Beranda › Kanker Ovarium › Colorado › Denver
Uji klinis Kanker Ovarium di Denver, CO
16 studi untuk Kanker Ovarium mencari peserta di lokasi sekitar Denver (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
The Vanguard Study: Testing a New Way to Screen for Cancer
Menerima pesertaSukarelawan sehat diterima
- Kaiser Permanente-Franklin, Denver
A Study of PHST001 in Advanced Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One, Denver
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute at HealthOne, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- Rocky Mountain Cancer Center, Denver
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1
- SCRI at HealthOne, Denver
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Menerima pesertaFase 1
- Sarah Cannon Research Institute at HealthONE /ID# 278785, Denver
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Menerima pesertaFase 3
- AdventHealth Medical Group - Porter, Denver
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Menerima pesertaFase 1/2
- SCRI at HCA Health One, Denver
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Menerima pesertaFase 1
- Sarah Cannon Research Institute - Denver DDU, Denver
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Menerima pesertaFase 1
- Normunity Investigational Site, Denver
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Menerima pesertaFase 3
- Cancer Center of Colorado at Sloan's Lake, Denver
- UCHealth - Cherry Creek, Denver
- Saint Joseph Hospital - Cancer Centers of Colorado, Denver
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Rocky Mountain Cancer Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Menerima pesertaFase 1/2
- Research Site, Denver
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute at HealthONE, Denver
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Menerima pesertaFase 1
- Dren Investigational Site, Denver
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Denver
Uji klinis Kanker Ovarium di kota lain
- Houston, TX89 studi
- New York City, NY69 studi
- Boston, MA61 studi
- Los Angeles, CA50 studi
- Nashville, TN49 studi
- Arlington, VA46 studi
- Philadelphia, PA44 studi
- Columbus, OH39 studi
- St. Louis, MO38 studi
- Chicago, IL36 studi
- San Antonio, TX31 studi
- Cleveland, OH30 studi
Studi lain di Denver
- Kanker Metastatik29 studi
- Kanker Payudara29 studi
- Kanker Paru Non-Sel Kecil27 studi
- Mieloma Multipel27 studi
- Kanker Kolorektal23 studi
- Melanoma19 studi
- Kanker Prostat19 studi
- Kanker (semua jenis)18 studi
- Kanker Paru16 studi
- Kanker Endometrium15 studi
- Limfoma Non-Hodgkin14 studi
- Kanker Pankreas13 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.